Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and rais

Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

U.S. stock futures rise, Meta shares drop 9.4%, Teladoc Health and Rentokil Initial fall after mixed

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

MiMedx Group NASDAQ: MDXG said it has agreed to acquire Sanara MedTech in a transaction valued at $3

MiMedx Group (NASDAQ:MDXG) affirms FY2026 sales outlook from $260.000 million-$290.000 million to $2

MiMedx Group (NASDAQ:MDXG) reported quarterly losses of $(0.05) per share which met the analyst cons

Reports  Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standal

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgica

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgica

MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc.

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

Investors need to pay close attention to MDXG stock based on the movements in the options market lat

MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 mi

Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plu

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o

Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and

MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript

MiMedx (MDXG) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate

MiMedx Group (NASDAQ:MDXG) reported quarterly losses of $(0.05) per share which missed the analyst c

MiMedx Group (NASDAQ:MDXG) lowers FY2026 sales outlook from $340.000 million-$360.000 million to $26

Reports  First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectati

Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and

Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and lowe

MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the com

MiMedx Group (NASDAQ:MDXG) sees FY2026 sales of $340.000 million-$360.000 million vs $376.533 millio

MiMedx Group (NASDAQ:MDXG) reported quarterly earnings of $0.14 per share which beat the analyst con

Citizens analyst David Turkaly initiates coverage on MiMedx Group (NASDAQ:MDXG) with a Market Out

Cantor Fitzgerald analyst Sarah James maintains MiMedx Group (NASDAQ:MDXG) with a Overweight and

MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced it has

Lake Street analyst Brooks O'Neil maintains MiMedx Group (NASDAQ:MDXG) with a Buy and lowers

MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced it has

Mizuho analyst Anthony Petrone maintains MiMedx Group (NASDAQ:MDXG) with a Outperform and lowers

MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the pub